SARC-PAZO-CHONDRO

NCT01330966 📎

Regimen

Experimental
Pazopanib 800 mg PO QD continuous (multi-kinase VEGFR/PDGFR/KIT inhibitor)
Control
none (single-arm)

Population

Surgically unresectable or metastatic chondrosarcoma (conventional, dedifferentiated, mesenchymal subtypes allowed), progressive disease required at entry

Key finding

Modest but real disease-control signal in conventional chondrosarcoma with pazopanib — enough to justify the drug as a non-IDH option in a disease with no chemotherapy. Dedifferentiated chondrosarcoma fared worse.

Source: PMID 31509242

Timeline

    Guideline citations

    • NCCN BONE (p.89)